For the first time in the history of Alzheimer's disease treatment, patients can now start an anti-amyloid therapy at home. On July 13, 2026, the U.S. Food and Drug Administration approved LEQEMBI IQLIK, a once-weekly subcutaneous injection of lecanemab-irmb that patients and care partners can administer themselves via autoinjector, without visiting a hospital or infusion center. The approval was announced jointly by Eisai and Biogen, the drug's co-developers, and the U.S. commercial launch is expected in late August 2026 through specialty pharmacy.
The significance of this approval extends well beyond a new delivery mechanism. The previous Leqembi regimen required patients to visit an infusion center every two weeks for 18 months simply to begin treatment, a logistical barrier that has kept many eligible patients from starting or staying on the drug. LEQEMBI IQLIK removes that barrier entirely.
